Company Overview and News


2018-03-21 globenewswire
Les actionnaires de la Société sont invités à participer à l'Assemblée Générale Mixte qui se tiendra le :


2018-03-21 globenewswire
Thursday, April 26, 2018 at 10:00 at the headquarters of SCOR SE 5, avenue Kléber 75016 Paris

Blog Exposure - Aegon Divests Chunk of Life Reinsurance Business to France's SCOR; Dissolves Related Captive Insurance Company

2018-01-02 accesswire
LONDON, UK / ACCESSWIRE / January 02, 2018 / has just released a free research report on AEGON N.V. (NYSE: AEG). If you want access to this report all you need to do is sign up now by clicking the following link as the Company's latest news hit the wire. On December 28, 2017, the Company disclosed that it has signed an agreement to sell off a chunk of its life reinsurance business to SCOR SE, a France based global reinsurance Company.

Deals of the day-Mergers and acquisitions

2017-12-28 reuters
Dec 28 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1030 GMT on Thursday:

Atlantic Hurricanes Wipe Out Reinsurers’ Profits in Europe - The New York Times

2017-10-26 nytimes
FRANKFURT — The financial damage from the hurricanes that struck Texas, Florida and the Caribbean in recent months crossed the Atlantic on Thursday when Munich Re, a German insurer, warned that virtually all of its profit this year would be wiped out by the horrendous cost of the disasters.

32% Increase in Ruschlikon Business Transactions in 2016

2017-05-24 marketwired
PEARL RIVER, NY--(Marketwired - May 24, 2017) - The success of Ruschlikon, the global community of insurers, brokers and reinsurers, continues with an expanded global footprint:

Is Scor (SCRYY) Stock A Great Combo of Value and Growth?

2017-04-18 zacks
Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?

Phoenix Group Holdings - 2016 Annual Results

2017-03-20 londonstockexchange
Phoenix Group, the UK's largest specialist closed life fund consolidator1, today announces a strong set of results for the year ended 31 December 2016.

'Indian insurance sector to grow significantly in coming yrs'

2017-01-16 moneycontrol
Ensure that your correct email id and mobile has been registered with moneycontrol. If not, please update your profile and secure the account now. Updating your email id and mobile number offers following benefits:

Kemper Unlikely to Recover Estimated Q1 Catastrophe Loss

2016-04-06 zacks
Kemper Corporation (KMPR - Snapshot Report) estimates catastrophe loss between $35 and $45 million to weigh on first-quarter 2016 earnings. The insurer is not hopeful of recovering any of these losses from its catastrophe reinsurance program. Though the pre-tax losses stemmed from various storms, the hail storm in north Texas on Mar 23 in particular was largely responsible for the consolidated loss.

Phoenix Group Holdings - 2015 Annual Results

2016-03-23 londonstockexchange
Phoenix Group, the UK's largest specialist closed life fund consolidator, today announces a strong set of results for the year ended 31 December 2015, with cash generation in line with the target range and £205 million of incremental embedded value achieved.

Traders Look to Upside - Analyst Research on Wolseley, Deutsche Boerse, Yahoo Japan and Scor

2016-01-25 accesswire
NEW YORK, NY / ACCESSWIRE / January 25, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Wolseley PLC (OTC: WOSYY), Deutsche Boerse AG (OTC: DBOEY), Yahoo Japan Corp. (OTC: YAHOY) and Scor SE (OTC: SCRYY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...